Trending...
- Spokane: Indian Canyon Golf Course Opens Thursday, March 12, 2026
- Spokane: City Council Adopts "Immigration Enforcement Free Zones" Ordinance
- Independent Financial Agencies Upgrade City of Tacoma's Bond Ratings Amid Broader Economic Uncertainty
STUART, Fla., April 19, 2024 ~ Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company, is making strides in the development of therapies for various eye disorders. The company's President and CEO, Eric Schlumpf, will be presenting their latest research results at two upcoming meetings in early May.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
- Danholm Collection Announces Sale of 16689 Broadwater Ave in Winter Garden, Highlighting Strong Performance in Twinwaters Community
- Strong Clinical Results for Breakthrough Liver Diagnostic Platform; ENDRA Life Sciences (N A S D A Q: NDRA) $NDRA
- 46th International Symposium On Forecasting – Dates, Venue And Speakers Announced
- Phoenix Rebellion Therapy Celebrates 10 Years Helping Utahns Overcome Trauma as Utah Faces Nation's 2nd-Highest Rate of Mental Health Challenges
- Bonavita Luxury & Portable Lavatories Announces Rebrand to Bonavita Site Solutions
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
0 Comments
Latest on Washingtoner
- Spokane: Indian Canyon Golf Course Opens Thursday, March 12, 2026
- Federal Contract Fraud: The GUBERMAN Anomaly Exposes Boeing–ANAB Collusion in Contract 19AQMM18R0131
- Simpalm Staffing Services Launched its Refreshed Website for Remote Staffing Services
- Claude Riveloux Review 2026: How the $10B Fund Manager Dispels 'Scam' Rumors Through Education
- Pure Energy Electrical Services, LLC Announces Strong Start to 2026, Reinforcing Customer-First Electrical Service Across Northeast Florida
- The GUBERMAN Anomaly: Boeing's Alliance with ANSI–ANAB Exposed in Federal Contract 19AQMM18R0131
- Danholm Collection Launches Boutique Luxury Real Estate Brokerage in Central Florida
- Sellvia Market Expands Curated Store Portfolio for Dropshipping Sellers
- Food Journal Magazine Raises the Standard for Restaurant Reviews in Los Angeles
- StaffReady Expands Its Clinical Workforce Platform with ScheduleReady Compliance and Scheduling Suite
- Williamsville Spa Expands Team to Meet Growing Demand for Professional Facials
- PNW Virtual Health Announces Grand Opening of New Downtown Seattle Clinic
- Pregis Expands Wind Energy Use, Advancing Progress Toward Net Zero by 2040
- Dr. Sheel Desai Solomon and Preston Dermatology Continue Awards Streak with Top Honors in 2026 Maggy Awards
- How Boeing's 2002 Mandates, ANAB's Federal Underwriter Fraud, and the 2026 GLOBAC Merger Exposed a Collapse in Certification Across All Industries
- Jack and Sage Acquires Sustainable Apparel Brand Kastlfel, Expanding Premium Logo Wear Across National Parks and Ski Resorts
- The Media Should Protect the Public When It Comes to Boeing — But Does It?
- Cancun International Airport Prepares for Record Travel Surge Ahead of Spring Break, Summer, and the 2026 High Season
- $167 Billion Pharma R&D Market Largely Untapped by AI Creates Major Growth Runway for KALA Bios Data-Sovereign AI Strategy: N A S D A Q: KALA
- Lighthouse Tech Awards Recognize Top HR Technology Providers for 2026